ACTengine® IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine® dose escalation is on track for Q1 2021 Expansion of UTHealth partnership secures cell therapy manufacturing capacities until end of 2024 Positive pre-clinical data updates on ACTengine®

Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence. Clinical courses observed in patients indicate COL6A3 exon 6 as a potentially valuable tumor target for continued evaluation.

Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics The IMA401 target, an HLA-A*02-bound peptide derived both from MAGEA4 and MAGEA8, shows >5-fold higher target

Tuebingen, Germany and Houston, Texas, September 29, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that Arnd Christ will join its leadership team as

Tuebingen, Germany and Houston, Texas, September 15, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the appointment of Eliot Forster, PhD, to its Board

Tuebingen, Germany and Houston, Texas, Sept. 10, 2020 (GLOBE NEWSWIRE) -- IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy numbers in tumor stroma across many solid cancers Two affinity-enhanced TCR candidates designed using

Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction totaling $253 million (€226 million 1 ) in July 2020. At the closing of the transaction, cash and cash

First patient has been treated in Germany in Immatics’ ACTengine^® IMA202-101 trial. Three clinical trial sites in Germany have started recruiting patients for Immatics’ ACTengine^® IMA200 trial series.

Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory

Immatics today announced changes to its Board of Directors in conjunction with its recent listing on NASDAQ. Michael Atieh, Paul Carter, Heather Mason and Adam Stone will join the Company’s board as new members.

Immatics today announced the completion of its business combination with Arya Sciences Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors.  Immatics N.V. will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market today.

Arya Sciences Acquisition Corp. and Immatics Biotechnologies GmbH today announced that its respective shareholders approved the business combination announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. 

Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics.

Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account. Leading institutional investors commit $104 million of cash through a common stock private investment in public equity (“PIPE”).

GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies. Immatics to receive €45 Million (~$50 Million) upfront payment with potential for additional milestone and royalty payments.